Drug Profile
RP G28
Alternative Names: RP-G28Latest Information Update: 26 May 2020
Price :
$50
*
At a glance
- Originator Ritter Pharmaceuticals
- Developer Qualigen Therapeutics; University of British Columbia
- Class Antineoplastics; Digestion aids; Oligosaccharides
- Mechanism of Action Bacterial growth stimulants; Carbohydrate metabolism stimulants; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer; Gastrointestinal disorders; Lactose intolerance; Liver disorders; Metabolic syndrome
Most Recent Events
- 19 May 2020 Ritter Pharmaceuticals has merged with Qualigen to form Qualigen Therapeutics
- 31 Dec 2019 Ritter Pharmaceuticals has patent protection for RP G28 in USA, Europe, Canada, Australia, India, Israel, Japan, Philippines, China and South Korea
- 12 Sep 2019 Top-line efficacy and safety data from the phase III Liberatus trial in Lactose intolerance released by Ritter Pharmaceuticals